Latest Filings

Issuer Activity

Overview :: ABIOMED, Inc. (OQ:ABMD) [?]
Business Focus: Advanced Medical Equipment & Technology Share on StockTwits
Recent Price for ABMD
USD 60.350 -1.030 (-1.678%)
NSQ Delayed 15 minutes
Mar 6 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
61.862 62.820 142.99 252,309 2,480.79
1-Day Low 52-Week Low Yield Avg. Volume  
60.220 20.290 0.0% NSQ  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for ABMD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 10:27pm ET March 6th, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Feb 26/15 Feb 24/15 Austen W Gerald Direct Ownership Common Stock, $0.01 par value S - Open market or private sale -6,000 $60.62
Feb 18/15 Feb 12/15 Austen W Gerald Direct Ownership Common Stock, $0.01 par value S - Open market or private sale -8,000 $58.65
Feb 4/15 Feb 2/15 Rose Eric A Md Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -15,000  
Feb 4/15 Feb 2/15 Rose Eric A Md Direct Ownership Common Stock, $.01 par value S - Open market or private sale -15,000 $51.44
Feb 4/15 Feb 2/15 Rose Eric A Md Direct Ownership Common Stock, $.01 par value M - Exercise or conversion exempt under rule 16b-3 15,000 $11.27
Feb 4/15 Feb 2/15 Weber David M Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -30,000  
Feb 4/15 Feb 2/15 Weber David M Direct Ownership Common Stock, $.01 par value S - Open market or private sale -30,000 $51.39
Feb 4/15 Feb 2/15 Weber David M Direct Ownership Common Stock, $.01 par value M - Exercise or conversion exempt under rule 16b-3 30,000 $13.88
Feb 4/15 Feb 2/15 Bolt William J Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -8,000  
Feb 4/15 Feb 2/15 Bolt William J Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -20,000  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for ABMD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 10:27pm ET March 6th, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Feb 26/15 Feb 24/15 Austen W Gerald Direct Ownership Common Stock, $0.01 par value S - Open market or private sale -6,000 $60.62
Feb 18/15 Feb 12/15 Austen W Gerald Direct Ownership Common Stock, $0.01 par value S - Open market or private sale -8,000 $58.65
Feb 4/15 Feb 2/15 Rose Eric A Md Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -15,000  
Feb 4/15 Feb 2/15 Rose Eric A Md Direct Ownership Common Stock, $.01 par value S - Open market or private sale -15,000 $51.44
Feb 4/15 Feb 2/15 Rose Eric A Md Direct Ownership Common Stock, $.01 par value M - Exercise or conversion exempt under rule 16b-3 15,000 $11.27
Feb 4/15 Feb 2/15 Weber David M Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -30,000  
Feb 4/15 Feb 2/15 Weber David M Direct Ownership Common Stock, $.01 par value S - Open market or private sale -30,000 $51.39
Feb 4/15 Feb 2/15 Weber David M Direct Ownership Common Stock, $.01 par value M - Exercise or conversion exempt under rule 16b-3 30,000 $13.88
Feb 4/15 Feb 2/15 Bolt William J Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -8,000  
Feb 4/15 Feb 2/15 Bolt William J Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -20,000  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Key People
Michael R. Minogue
Chairman of the Board, President, Chief Executive Officer
Robert L. Bowen
Chief Financial Officer, Vice President, Treasurer
David M. Weber
Chief Operating Officer
William J. Bolt
Senior Vice President - Global Product Operations
Andrew J. Greenfield
Vice President, General Manager - Global Marketing
Michael G. Howley
Vice President, General Manager - Global Sales and Marketing
Ingrid Goldberg
Director - Investor Relations
   
Company Contact
Address: 22 CHERRY HILL DR
DANVERS MA 01923
Tel: 1-978-6461590
Website: www.abiomed.com
IR: See website
Business Overview
ABIOMED, Inc. is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Impella 2.5 is introduced with normal interventional cardiology procedures and can pump up to 2.5 liters of blood per minute. The Company is conducting USpella, the United States multicenter observational registry collecting clinical data and outcomes for general use patients supported with Impella 2.5, CP and 5.0 during procedures.
Financial Overview
For the nine months ended 31 December 2014, ABIOMED, Inc. revenues increased 22% to $162.8M. Net income increased from $3.7M to $14.8M. Revenues reflect Funded research and development increase from $172K to $354K. Net income benefited from Investment (expense) income, net increase of 3% to $80K (income). Basic Earnings per Share excluding Extraordinary Items increased from $0.09 to $0.36.
Employees: 511 as of Mar 31, 2014
Reporting Currency: U.S. Dollars
Enterprise value: $2,410M as of Dec 31, 2014
Annual revenue (TTM): $213.19M as of Dec 31, 2014
EBITDA (TTM): $22.42M as of Dec 31, 2014
Net annual income (TTM): $18.44M as of Dec 31, 2014
Free cash flow (TTM): $32.23M as of Dec 31, 2014
Net Debt Last Fiscal Year: N/A
Shares outstanding: 41,106,708 as of Jan 23, 2015
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Illumina (OQ:ILMN)
Cerner (OQ:CERN)
Intuitive Surgical (OQ:ISRG)